Cited by 755Malaria Research and ControlBacterial Infections and VaccinesTravel-related health issues

The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.

A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants

Open access

The RTS,S Clinical Trials Partnership·2012·New England Journal of Medicine

DOI 10.1056/nejmoa1208394PMC PMC10915853

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The candidate malaria vaccine RTS,S/AS01 reduced episodes of both clinical and severe malaria in children 5 to 17 months of age by approximately 50% in an ongoing phase 3 trial. We studied infants 6 to 12 weeks of age recruited for the same trial. METHODS: We administered RTS,S/AS01 or a comparator vaccine to 6537 infants who were 6 to 12 weeks of age at the time of the first vaccination in conjunction with Expanded Program on Immunization (EPI) vaccines in a three-dose monthly schedule. Vaccine efficacy against the first or only episode of clinical malaria during the 12 months after vaccination, a coprimary end point, was analyzed with the use of Cox regression. Vaccine efficacy against all malaria episodes, vaccine efficacy against severe malaria, safety, and immunogenicity were also assessed. RESULTS: The incidence of the first or only episode of clinical malaria in the intention-to-treat population during the 14 months after the first dose of vaccine was 0.31 per person-year in the RTS,S/AS01 group and 0.40 per person-year in the control group, for a vaccine efficacy of 30.1% (95% confidence interval [CI], 23.6 to 36.1). Vaccine efficacy in the per-protocol population was 31.3% (97.5% CI, 23.6 to 38.3). Vaccine efficacy against severe malaria was 26.0% (95% CI, -7.4 to 48.6) in the intention-to-treat population and 36.6% (95% CI, 4.6 to 57.7) in the per-protocol population. Serious adverse events occurred with a similar frequency in the two study groups. One month after administration of the third dose of RTS,S/AS01, 99.7% of children were positive for anti-circumsporozoite antibodies, with a geometric mean titer of 209 EU per milliliter (95% CI, 197 to 222). CONCLUSIONS: The RTS,S/AS01 vaccine coadministered with EPI vaccines provided modest protection against both clinical and severe malaria in young infants. (Funded by GlaxoSmithKline Biologicals and the PATH Malaria Vaccine Initiative; RTS,S ClinicalTrials.gov number, NCT00866619.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1208394

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Modeling Survival Data: Extending the Cox Model
Therneau, T. M., & Grambsch, P. M. (2000) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3294-8 · Cited by 8,674
Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,975
First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children
The RTS, S. C. T. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102287 · Cited by 896
Self-citation
ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice.
Bhuiyan, P. S., & Rege, N. N. (2001) · PubMed · Cited by 527
Randomized, Double‐Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria‐Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection
Kester, K. E., Cummings, J. F., Ofori‐Anyinam, O., Ockenhouse, C. F., Krzych, U., Moris, P., Schwenk, R., Nielsen, R. A., Debebe, Z., Pinelis, E., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/600120 · Cited by 524
Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants
Siegrist, C. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00342-6 · Cited by 350
Design and Analysis of Vaccine Studies
Halloran, M. E., Longini, I. M., & Struchiner, C. J. (2009) · Statistics for biology and health · doi:10.1007/978-0-387-68636-3 · Cited by 332
Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial
Aponte, J. J., Aide, P., Renom, M., Mandomando, I., Bassat, Q., Sacarlal, J., Manaca, M. N., Lafuente, S., Barbosa, A., Leach, A., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61542-6 · Cited by 279
Glycoconjugate vaccines and immune interference: A review
Dagan, R., POOLMAN, J. T., & Siegrist, C. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.06.026 · Cited by 270
Safety and Immunogenicity of RTS,S/AS02D Malaria Vaccine in Infants
Abdulla, S., Oberholzer, R., Juma, O. A., Kubhoja, S. D., Machera, F., Membi, C. D., Omari, S., Urassa, A., Mshinda, H., Jumanne, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807773 · Cited by 239

Flagged first, then by citations

Show all 31 references

1 of the 31 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Brabin B, 1990, Trop Dis Bull, 87, R1

Sorted by citations

Items 201–300 of 755

Impact of Malaria Preexposure on Antiparasite Cellular and Humoral Immune Responses after Controlled Human Malaria Infection
Obiero, J. M., Shekalaghe, S. A., Hermsen, C. C., Mpina, M., Bijker, E. M., Roestenberg, M., Teelen, K., Billingsley, P. F., Sim, B. K. L., James, E. R., et al. (2015) · Infection and Immunity · doi:10.1128/iai.03069-14 · Cited by 43
Acceptance of a malaria vaccine by caregivers of sick children in Kenya
Ojakaa, D. I., Jarvis, J. D., Inziani, M., & Thiam, S. (2014) · Malaria Journal · doi:10.1186/1475-2875-13-172 · Cited by 43
Recent advancements in combination subunit vaccine development
Tan, M., & Jiang, X. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1229719 · Cited by 43
The effect of immunization schedule with the malaria vaccine candidate RTS,S/AS01E on protective efficacy and anti-circumsporozoite protein antibody avidity in African infants
Ajua, A., Lell, B., Agnandji, S. T., Asante, K. P., Owusu‐Agyei, S., Mwangoka, G., Mpina, M., Salim, N., Tanner, M., Abdulla, S., et al. (2015) · Malaria Journal · doi:10.1186/s12936-015-0605-7 · Cited by 44
Peripheral blood monocyte-to-lymphocyte ratio at study enrollment predicts efficacy of the RTS,S malaria vaccine: analysis of pooled phase II clinical trial data
Warimwe, G. M., Fletcher, H. A., Olotu, A., Agnandji, S. T., Hill, A. V. S., Marsh, K., & Bejon, P. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-184 · Cited by 42
Application of wheat germ cell-free protein expression system for novel malaria vaccine candidate discovery
Arumugam, T. U., Ito, D., Takashima, E., Tachibana, M., Ishino, T., Torii, M., & Tsuboi, T. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2014.861747 · Cited by 42
Genetic diversity and antibody responses against Plasmodium falciparum vaccine candidate genes from Chhattisgarh, Central India: Implication for vaccine development
Patel, P. P., Bharti, P. K., Bansal, D., Raman, R. K., Mohapatra, P. K., Sehgal, R., Mahanta, J., Sultan, A. A., & Singh, N. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182674 · Cited by 42
CCR2- and Flt3-Dependent Inflammatory Conventional Type 2 Dendritic Cells Are Necessary for the Induction of Adaptive Immunity by the Human Vaccine Adjuvant System AS01
Bosteels, C., Fierens, K., Prijck, S. D., Moorleghem, J. V., Vanheerswynghels, M., Wolf, C. D., Chalon, A., Collignon, C., Hammad, H., Didierlaurent, A. M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.606805 · Cited by 43
A modular and self-adjuvanted multivalent vaccine platform based on porcine circovirus virus-like nanoparticles
Liu, Z., Deng, Z., Lu, Y., Fang, W., & He, F. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01710-4 · Cited by 44
Vaccine preventable disease incidence as a complement to vaccine efficacy for setting vaccine policy
Gessner, B. D., & Feikin, D. R. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.04.019 · Cited by 41
The public health impact of malaria vaccine RTS,S in malaria endemic Africa: country-specific predictions using 18 month follow-up Phase III data and simulation models
Penny, M. A., Galactionova, K., Tarantino, M., Tanner, M., & Smith, T. A. (2015) · BMC Medicine · doi:10.1186/s12916-015-0408-2 · Cited by 46
RTS,S/AS01E Malaria Vaccine Induces Memory and Polyfunctional T Cell Responses in a Pediatric African Phase III Trial
Moncunill, G., Rosa, S. C. D., Ayestaran, A., Nhabomba, A. J., Mpina, M., Cohen, K. W., Jairoce, C., Rutishauser, T., Campo, J. J., Harezlak, J., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01008 · Cited by 43
CXCR3+ T Follicular Helper Cells Induced by Co-Administration of RTS,S/AS01B and Viral-Vectored Vaccines Are Associated With Reduced Immunogenicity and Efficacy Against Malaria
Bowyer, G., Grobbelaar, A., Rampling, T., Venkatraman, N., Morelle, D., Ballou, R. W., Hill, A. V. S., & Ewer, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01660 · Cited by 41
Functional human IgA targets a conserved site on malaria sporozoites
Tan, J., Cho, H., Pholcharee, T., Pereira, L. D. S., Doumbo, S., Doumtabé, D., Flynn, B. J., Schön, A., Kanatani, S., Aylor, S. O., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abg2344 · Cited by 41
Liposomes for malaria management: the evolution from 1980 to 2020
Memvanga, P. B., & Nkanga, C. I. (2021) · Malaria Journal · doi:10.1186/s12936-021-03858-0 · Cited by 45
Antimalarial drug resistance: new treatments options for Plasmodium
Gamo, F. (2014) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2014.03.002 · Cited by 41
Subviral particle as vaccine and vaccine platform
Tan, M., & Jiang, X. (2014) · Current Opinion in Virology · doi:10.1016/j.coviro.2014.02.009 · Cited by 40
Vaccines for low-income countries
MacLennan, C. A. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.05.004 · Cited by 41
Health & Demographic Surveillance System Profile: The Kombewa Health and Demographic Surveillance System (Kombewa HDSS)
Sifuna, P., Oyugi, M., Ogutu, B. R., Andagalu, B. M., Otieno, A., Owira, V., Otsyula, N., Oyieko, J. N., Cowden, J., Otieno, L., et al. (2014) · International Journal of Epidemiology · doi:10.1093/ije/dyu139 · Cited by 40
Optimal vaccination and bednet maintenance for the control of malaria in a region with naturally acquired immunity
Prosper, O., Ruktanonchai, N., & Martcheva, M. (2014) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2014.03.013 · Cited by 39
Evaluating antidisease immunity to malaria and implications for vaccine design
Ademolue, T. W., & Awandare, G. A. (2017) · Immunology · doi:10.1111/imm.12877 · Cited by 39
Recent Developments in Malaria Vaccinology
Halbroth, B. R., & Draper, S. J. (2015) · Advances in Parasitology/Advances in parasitology · doi:10.1016/bs.apar.2015.03.001 · Cited by 41
A brief history of malaria
Nosten, F. H., Richard-Lenoble, D., & Danis, M. (2022) · La Presse Médicale · doi:10.1016/j.lpm.2022.104130 · Cited by 47
Experience and challenges from clinical trials with malaria vaccines in Africa
Mwangoka, G., Ogutu, B. R., Msambichaka, B., Mzee, T., Salim, N., Shubis, K., Mpina, M., Shekalaghe, S., Tanner, M., & Abdulla, S. (2013) · Malaria Journal · doi:10.1186/1475-2875-12-86 · Cited by 42
Malaria vaccine based on self-assembling protein nanoparticles
Burkhard, P., & Lanar, D. E. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.1096781 · Cited by 40
The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment
Goodman, A. L., Forbes, E. K., Williams, A. R., Douglas, A. D., de Cassan, S. C., Bauza, K., Biswas, S., Dicks, M. D. J., Llewellyn, D., Moore, A., et al. (2013) · Scientific Reports · doi:10.1038/srep01706 · Cited by 39
Plasmodium vivax malaria vaccines: Why are we where we are?
Reyes‐Sandoval, A., & Bachmann, M. F. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.26157 · Cited by 39
Clinical development of placental malaria vaccines and immunoassays harmonization: a workshop report
Chêne, A., Houard, S. A., Nielsen, M. A., Hundt, S., D’Alessio, F., Sirima, S. B., Luty, A. J. F., Duffy, P. E., Leroy, O. Y., Gamain, B., et al. (2016) · Malaria Journal · doi:10.1186/s12936-016-1527-8 · Cited by 40
Expeditious recruitment of circulating memory CD8 T cells to the liver facilitates control of malaria
Lefebvre, M. N., Surette, F. A., Anthony, S. M., Vijay, R., Jensen, I. J., Pewe, L. L., Hancox, L. S., Budimir, N., van de Wall, S., Urban, S. L., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109956 · Cited by 37
The P. falciparum CSP repeat region contains three distinct epitopes required for protection by antibodies in vivo
Flores-García, Y., Wang, L., Park, M., Asady, B., Idris, A. H., Kisalu, N. K., Muñoz, C. A., Pereira, L. D. S., Francica, J. R., Seder, R. A., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1010042 · Cited by 39
Assessing the safety, impact and effectiveness of RTS,S/AS01E malaria vaccine following its introduction in three sub-Saharan African countries: methodological approaches and study set-up
Praet, N., Asante, K. P., Bozonnat, M., Akité, E. J., Ansah, P. B., Baril, L., Boahen, O., Mendoza, Y. G., Haine, V., Kariuki, S., et al. (2022) · Malaria Journal · doi:10.1186/s12936-022-04144-3 · Cited by 39
Host-parasite interactions during Plasmodium infection: Implications for immunotherapies
Chandley, P., Ranjan, R., Kumar, S., & Rohatgi, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1091961 · Cited by 45
Challenges of assessing the clinical efficacy of asexual blood-stagePlasmodium falciparummalaria vaccines
Hodgson, S. H. C., Douglas, A. D., & Draper, S. J. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.25383 · Cited by 38
Plant-Based Production of Recombinant Plasmodium Surface Protein Pf38 and Evaluation of its Potential as a Vaccine Candidate
Feller, T., Thom, P., Koch, N., Spiegel, H., Addai‐Mensah, O., Fischer, R., Reimann, A., Pradel, G., Fendel, R., Schillberg, S., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079920 · Cited by 39
Vaccine approaches to malaria control and elimination: Insights from mathematical models
White, M. T., Verity, R., Churcher, T. S., & Ghani, A. C. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.09.099 · Cited by 40
Antibody responses to α-Gal in African children vary with age and site and are associated with malaria protection
Aguilar, R., Ubillos, I., Vidal, M., Balanza, N., Crespo, N., Jiménez, A., Nhabomba, A. J., Jairoce, C., Dosoo, D., Gyan, B. A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-28325-w · Cited by 38
Qualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions with Plasmodium falciparum Circumsporozoite Protein Antigens
Dennison, S. M., Reichartz, M., Seaton, K. E., Dutta, S., Wille-Reece, U., Hill, A. V. S., Ewer, K., Rountree, W., Sarzotti‐Kelsoe, M., Ozaki, D. A., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800323 · Cited by 42
Comprehensive Review of Human Plasmodium falciparum-Specific CD8+ T Cell Epitopes
Heide, J., Vaughan, K. C., Sette, A., Jacobs, T., & Wiesch, J. S. Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00397 · Cited by 42
Infectiousness of the Human Population to Anopheles arabiensis by Direct Skin Feeding in an Area Hypoendemic for Malaria in Senegal
Gaye, A., Bousema, T., Gadiaga, L., Ndiath, M. O., Konaté, L., Jawara, M., Faye, O., & Sokhna, C. (2015) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.14-0402 · Cited by 37
Ligand-Induced Conformational Change of Plasmodium falciparum AMA1 Detected Using 19F NMR
Ge, X., MacRaild, C. A., Devine, S. M., Debono, C. O., Wang, G., Scammells, P. J., Scanlon, M. J., Anders, R. F., Foley, M., & Norton, R. S. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500390g · Cited by 37
Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™
Venkatraman, N., Anagnostou, N. A., Bliss, C. M., Bowyer, G., Wright, D., Lövgren‐Bengtsson, K., Roberts, R., Poulton, I. D., Lawrie, A. M., Ewer, K., et al. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.09.028 · Cited by 38
The US Military Commitment to Vaccine Development: A Century of Successes and Challenges
Ratto‐Kim, S., Yoon, I.-K., Paris, R., Excler, J., Kim, J. H., & O’Connell, R. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01397 · Cited by 36
Controlled Human Malaria Infection in Semi-Immune Kenyan Adults (CHMI-SIKA): a study protocol to investigate in vivo Plasmodium falciparum malaria parasite growth in the context of pre-existing immunity
Kapulu, M. C., Njuguna, P., Hamaluba, M., & CHMI-SIKA Study Team (2018) · Wellcome Open Research · doi:10.12688/wellcomeopenres.14909.2 · Cited by 40
RTS,S/AS01E immunization increases antibody responses to vaccine-unrelated Plasmodium falciparum antigens associated with protection against clinical malaria in African children: a case-control study
Dobaño, C., Ubillos, I., Jairoce, C., Gyan, B. A., Vidal, M., Jiménez, A., Santano, R., Dosoo, D., Nhabomba, A. J., Ayestaran, A., et al. (2019) · BMC Medicine · doi:10.1186/s12916-019-1378-6 · Cited by 38
Discriminating Protective from Nonprotective Plasmodium-Specific CD8+ T Cell Responses
Doll, K. L., Pewe, L. L., Kurup, S. P., & Harty, J. T. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600155 · Cited by 39
Tailoring a Plasmodium vivax Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral Vectors
Atcheson, E., Bauza, K., Salman, A. M., Alves, E. R., Blight, J., Viveros‐Sandoval, M. E., Janse, C. J., Khan, S. M., Hill, A. V. S., & Reyes‐Sandoval, A. (2018) · Infection and Immunity · doi:10.1128/iai.00114-18 · Cited by 37
Malaria vaccine efficacy, safety, and community perception in Africa: a scoping review of recent empirical studies
Chutiyami, M., Saravanakumar, P., Bello, U. M., Salihu, D., Adeleye, K. K., Kolo, M. A., Dawa, K. K., Hamina, D., Bhandari, P., Sulaiman, S. K., et al. (2024) · Infection · doi:10.1007/s15010-024-02196-y · Cited by 36
New insights into the protective power of platelets in malaria infection
McMorran, B. J., Burgio, G., & Foote, S. J. (2013) · Communicative & Integrative Biology · doi:10.4161/cib.23653 · Cited by 36
Duration of vaccine efficacy against malaria: 5th year of follow-up in children vaccinated with RTS,S/AS02 in Mozambique
Campo, J. J., Sacarlal, J., Aponte, J. J., Aíde, P., Nhabomba, A. J., Dobaño, C., & Alonso, P. L. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.02.042 · Cited by 38
The effect of stable macromolecular complexes of ionic polyphosphazene on HIV Gag antigen and on activation of human dendritic cells and presentation to T-cells
Palmer, C. D., Ninković, J., Prokopowicz, Z. M., Mancuso, C. J., Marin, A., Andrianov, A. K., Dowling, D. J., & Levy, O. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.06.043 · Cited by 36
RTS,S Vaccination Is Associated With Serologic Evidence of Decreased Exposure to Plasmodium falciparum Liver- and Blood-Stage Parasites*
Campo, J. J., Aponte, J. J., Skinner, J., Nakajima, R., Molina, D. M., Liang, L., Sacarlal, J., Alonso, P. L., Crompton, P. D., Felgner, P. L., et al. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.044677 · Cited by 36
Malaria Vaccine Adjuvants: Latest Update and Challenges in Preclinical and Clinical Research
Mata, E., Salvador, A., Igartúa, M., Hernández, R. M., & Pedraz, J. L. (2013) · BioMed Research International · doi:10.1155/2013/282913 · Cited by 36
Detailed functional characterization of glycosylated and nonglycosylated variants of malaria vaccine candidate Pf AMA 1 produced in Nicotiana benthamiana and analysis of growth inhibitory responses in rabbits
Boes, A., Spiegel, H., Edgue, G., Kapelski, S., Scheuermayer, M., Fendel, R., Remarque, E. J., Altmann, F., Maresch, D., Reimann, A., et al. (2014) · Plant Biotechnology Journal · doi:10.1111/pbi.12255 · Cited by 36
Beyond efficacy: The full public health impact of vaccines
Saadatian‐Elahi, M., Horstick, O., Breiman, R. F., Gessner, B. D., Gubler, D. J., Louis, J. A., Parashar, U. D., TAPIA-CONYER, R. C., Picot, V., Zinsou, J.-A., et al. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.01.021 · Cited by 39
Factors Associated with Retention to Care in an HIV Clinic in Gabon, Central Africa
Janssen, S., Wieten, R. W., Stolp, S. M., Cremers, A. L., Rossatanga, E. G., Klipstein‐Grobusch, K., Bélard, S., & Grobusch, M. P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140746 · Cited by 36
Routine malaria vaccination in Africa: a step toward malaria eradication?
Sibomana, O., Bukuru, J., Saka, S. A., Uwizeyimana, M. G., Kihunyu, A. M., Obianke, A., Damilare, S. O., Bueh, L. T., Agbelemoge, B. O. G., & Oveh, R. O. (2025) · Malaria Journal · doi:10.1186/s12936-024-05235-z · Cited by 35
Using Mutagenesis and Structural Biology to Map the Binding Site for the Plasmodium falciparum Merozoite Protein PfRh4 on the Human Immune Adherence Receptor
Park, H. J., Guariento, M., Maciejewski, M., Hauhart, R. E., Tham, W., Cowman, A. F., Schmidt, C. Q., Mertens, H. D. T., Liszewski, M. K., Hourcade, D. E., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.520346 · Cited by 35
Optimization of a Plasmodium falciparum circumsporozoite protein repeat vaccine using the tobacco mosaic virus platform
Langowski, M. D., Khan, F. A., Bitzer, A. A., Genito, C. J., Schrader, A. J., Martin, M. L., Soto, K., Zou, X., Hadiwidjojo, S., Beck, Z., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1911792117 · Cited by 36
Dietary flavonoids fisetin and myricetin: Dual inhibitors of Plasmodium falciparum falcipain-2 and plasmepsin II
Jin, H., Xu, Z., Cui, K., Zhang, T., Lü, W., & Huang, J. Y. (2014) · Fitoterapia · doi:10.1016/j.fitote.2014.01.017 · Cited by 37
Immunogenicity of a Prime-Boost Vaccine Containing the Circumsporozoite Proteins of Plasmodium vivax in Rodents
Teixeira, L. H., Tararam, C. A., Lasaro, M. O., Camacho, A. G. A., Ersching, J., Leal, M. T., Herrera, S. V., Bruña–Romero, O., Soares, I. S., Nussenzweig, R. S., et al. (2013) · Infection and Immunity · doi:10.1128/iai.01410-13 · Cited by 35
mRNA vaccines expressing malaria transmission-blocking antigens Pfs25 and Pfs230D1 induce a functional immune response
Scaria, P. V., Roth, N., Schwendt, K., Muratova, O. V., Alani, N., Lambert, L., Barnafo, E. K., Rowe, C. G., Zaidi, I., Rausch, K. M., et al. (2024) · npj Vaccines · doi:10.1038/s41541-023-00783-y · Cited by 36
Human immune system mice immunized with Plasmodium falciparum circumsporozoite protein induce protective human humoral immunity against malaria
Huang, J., Li, X., Coelho-dos-Reis, J. G. A., Zhang, M., Mitchell, R. A., Nogueira, R. T., Tsao, T., Noe, A. R., Ayala, R., Sahi, V., et al. (2015) · Journal of Immunological Methods · doi:10.1016/j.jim.2015.09.005 · Cited by 34
Variation in the Circumsporozoite Protein of Plasmodium falciparum: Vaccine Development Implications
Gandhi, K., Thera, M. A., Coulibaly, D. M., Traoré, K., Guindo, A. B., Ouattara, A., Takala‐Harrison, S., Berry, A. A., Doumbo, O. K., & Plowe, C. V. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101783 · Cited by 34
Mechanisms of Stage-Transcending Protection Following Immunization of Mice with Late Liver Stage-Arresting Genetically Attenuated Malaria Parasites
Sack, B. K., Keitany, G. J., Vaughan, A. M., Miller, J. L., Wang, R., & Kappe, S. H. I. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1004855 · Cited by 34
Safety and immunogenicity of RTS,S/AS01 malaria vaccine in infants and children with WHO stage 1 or 2 HIV disease: a randomised, double-blind, controlled trial
Otieno, L., Oneko, M., Otieno, W., Abuodha, J., Owino, E., Odero, C., Mendoza, Y. G., Andagalu, B., Awino, N., Ivinson, K., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30161-x · Cited by 34
Genetic polymorphism and natural selection of circumsporozoite surface protein in Plasmodium falciparum field isolates from Myanmar
Lê, H. G., Kang, J., Moe, M., Jun, H., Thái, T. L., Lee, J., Myint, M. K., Lin, K., Sohn, W., Shin, H., et al. (2018) · Malaria Journal · doi:10.1186/s12936-018-2513-0 · Cited by 33
Malaria oocysts require circumsporozoite protein to evade mosquito immunity
Zhu, F., Zheng, H., Chen, S., Zhang, K., Qin, X., Zhang, J., Liu, T., Fan, Y., Wang, L., Li, X., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30988-z · Cited by 34
The Lymphatic Immune Response Induced by the Adjuvant AS01: A Comparison of Intramuscular and Subcutaneous Immunization Routes
Neeland, M. R., Shi, W., Collignon, C., Taubenheim, N., Meeusen, E. N. T., Didierlaurent, A. M., & de Veer, M. J. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600817 · Cited by 33
Protozoan parasites and type I interferons: a cold case reopened
Beiting, D. P. (2014) · Trends in Parasitology · doi:10.1016/j.pt.2014.07.007 · Cited by 33
Imaging murine NALT following intranasal immunization with flagellin-modified circumsporozoite protein malaria vaccines
Nacer, A., Carapau, D., Mitchell, R. A., Meltzer, A., SHAW, A. R., Frevert, U., & Nardin, E. H. (2013) · Mucosal Immunology · doi:10.1038/mi.2013.48 · Cited by 37
Stakeholders’ opinions and questions regarding the anticipated malaria vaccine in Tanzania
Mtenga, S., Kimweri, A., Romore, I., Ali, A., Exavery, A., Sicuri, E., Tanner, M., Abdulla, S., Lusingu, J., & Kafuruki, S. (2016) · Malaria Journal · doi:10.1186/s12936-016-1209-6 · Cited by 37
Contribution of TLR4 and MyD88 for adjuvant monophosphoryl lipid A (MPLA) activity in a DNA prime–protein boost HIV-1 vaccine
Pouliot, K., Buglione‐Corbett, R., Marty-Roix, R., Paquette, S. W. M., West, K., Wang, S., Lu, S., & Lien, E. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.07.010 · Cited by 34
Protective Humoral Immunity Elicited by a Needle-Free Malaria Vaccine Comprised of a Chimeric Plasmodium falciparum Circumsporozoite Protein and a Toll-Like Receptor 5 Agonist, Flagellin
Carapau, D., Mitchell, R. A., Nacer, A., SHAW, A. R., Othoro, C., Frevert, U., & Nardin, E. H. (2013) · Infection and Immunity · doi:10.1128/iai.00263-13 · Cited by 32
High Antibody Responses against Plasmodium falciparum in Immigrants after Extended Periods of Interrupted Exposure to Malaria
Moncunill, G., Mayor, A. G., Jiménez, A., Nhabomba, A. J., Casas-Vila, N., Puyol, L., Campo, J. J., Manaca, M. N., Aguilar, R., Pinazo, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073624 · Cited by 32
Distinct Helper T Cell Type 1 and 2 Responses Associated With Malaria Protection and Risk in RTS,S/AS01E Vaccinees
Moncunill, G., Mpina, M., Nhabomba, A. J., Aguilar, R., Ayestaran, A., Sanz, H., Campo, J. J., Jairoce, C., Barrios, D., Dong, Y., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix429 · Cited by 31
Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults
Creech, C. B., Dekker, C. L., Ho, D. Y., Phillips, S., Mackey, S., Murray-Krezan, C. M., Pau, M. G., Hendriks, J., Brown, V. I., Dally, L. G., et al. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.26038 · Cited by 31
The whole parasite, pre-erythrocytic stage approach to malaria vaccine development
Epstein, J. E., & Richie, T. L. (2013) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000002 · Cited by 34
Country specific predictions of the cost-effectiveness of malaria vaccine RTS,S/AS01 in endemic Africa
Galactionova, K., Tediosi, F., Camponovo, F., Smith, T. A., Gething, P. W., & Penny, M. A. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.11.042 · Cited by 33
Combination of RTS,S and Pfs25-IMX313 Induces a Functional Antibody Response Against Malaria Infection and Transmission in Mice
Brod, F., Miura, K., Taylor, I. J., Li, Y., Marini, A., Salman, A. M., Spencer, A. J., Long, C. A., & Biswas, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02780 · Cited by 31
Infectious Diseases of Poverty in Children
Hansen, C. E., & Paintsil, E. (2015) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2015.08.002 · Cited by 32
Novel approaches to identify protective malaria vaccine candidates
Chia, W. N., Goh, Y. S., & Rénia, L. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00586 · Cited by 33
An epidemiological study to assess Plasmodium falciparum parasite prevalence and malaria control measures in Burkina Faso and Senegal
Diallo, A., Sié, A., Sirima, S. B., Sylla, K., Ndiaye, M., Bountogo, M., Ouédraogo, E., Tine, R. C. K., Ndiaye, A., Coulibaly, B., et al. (2017) · Malaria Journal · doi:10.1186/s12936-017-1715-1 · Cited by 28
Adjuvants containing natural and synthetic Toll-like receptor 4 ligands
Ireton, G. C., & Reed, S. G. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2013.811204 · Cited by 30
IMPIPS: The Immune Protection-Inducing Protein Structure Concept in the Search for Steric-Electron and Topochemical Principles for Complete Fully-Protective Chemically Synthesised Vaccine Development
Patarroyo, M. E., Bermúdez, A., Alba, M. P., Vanegas, M., Moreno-Vranich, A., Poloche, L. A., & Patarroyo, M. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123249 · Cited by 29
Malaria vaccine candidate antigen targeting the pre‐erythrocytic stage of Plasmodium falciparum produced at high level in plants
Voepel, N., Boes, A., Edgü, G., Beiss, V., Kapelski, S., Reimann, A., Schillberg, S., Pradel, G., Fendel, R., Scheuermayer, M., et al. (2014) · Biotechnology Journal · doi:10.1002/biot.201400350 · Cited by 30
Assessment of parental perception of malaria vaccine in Tanzania
Romore, I., Ali, A. M., Semali, I. A., Mshinda, H., Tanner, M., & Abdulla, S. (2015) · Malaria Journal · doi:10.1186/s12936-015-0889-7 · Cited by 28
Plasmodium sporozoites induce regulatory macrophages
Winkel, B. M. F., Pelgrom, L. R., van Schuijlenburg, R., Baalbergen, E., Ganesh, M. S., Gerritsma, H., de Korne, C. M., Duszenko, N., Langenberg, M. C. C., Chevalley, S., et al. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008799 · Cited by 28
OMIP‐025: Evaluation of human T ‐ and NK ‐cell responses including memory and follicular helper phenotype by intracellular cytokine staining
Moncunill, G., Dobaño, C., McElrath, M. J., & Rosa, S. C. D. (2014) · Cytometry Part A · doi:10.1002/cyto.a.22590 · Cited by 28
Leishmania donovani Nucleoside Hydrolase Terminal Domains in Cross-Protective Immunotherapy Against Leishmania amazonensis Murine Infection
Nico, D., Gomes, D. C., de Sousa, I. P., Morrot, A., Palatnik, M., & Palatnik, M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00273 · Cited by 28
Protective Efficacy of Baculovirus Dual Expression System Vaccine Expressing Plasmodium falciparum Circumsporozoite Protein
Iyori, M., Nakaya, H., Inagaki, K., Pichyangkul, S., Yamamoto, D. S., Kawasaki, M., Kwak, K., Mizukoshi, M., Gotō, Y., Matsuoka, H., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070819 · Cited by 27
Cost-effectiveness analysis of vaccinating children in Malawi with RTS,S vaccines in comparison with long-lasting insecticide-treated nets
Seo, M. K., Baker, P., & Ngo, K. N.-L. (2014) · Malaria Journal · doi:10.1186/1475-2875-13-66 · Cited by 28
Costing RTS,S introduction in Burkina Faso, Ghana, Kenya, Senegal, Tanzania, and Uganda: A generalizable approach drawing on publicly available data
Galactionova, K., Bertram, M., Lauer, J. A., & Tediosi, F. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.10.079 · Cited by 28
Are we entering a new age for human vaccine adjuvants?
O’Hagan, D. T., & Fox, C. B. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.1043273 · Cited by 28
Integration of the RTS,S/AS01 malaria vaccine into the Essential Programme on Immunisation in western Kenya: a qualitative longitudinal study from the health system perspective
Hill, J., Bange, T., Hoyt, J., Kariuki, S., Jalloh, M. F., Webster, J., & Okello, G. R. (2024) · The Lancet Global Health · doi:10.1016/s2214-109x(24)00013-5 · Cited by 27
Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial
Mensah, V. A., Roetynck, S., Kanteh, E., Bowyer, G., Ndaw, A., Oko, F., Bliss, C. M., Jagne, Y. J., Cortese, R., Nicosia, A., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01551 · Cited by 27
The Plasmodium falciparum circumsporozoite protein produced in Lactococcus lactis is pure and stable
Singh, S. K., Plieskatt, J. L., Chourasia, B. K., Singh, V., Bolscher, J. M., Dechering, K. J., Adu, B., Mendez, B. L., Kaviraj, S., Locke, E., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011268 · Cited by 33
OMIP ‐024: Pan‐leukocyte immunophenotypic characterization of PBMC subsets in human samples
Moncunill, G., Han, H., Dobaño, C., McElrath, M. J., & Rosa, S. C. D. (2014) · Cytometry Part A · doi:10.1002/cyto.a.22580 · Cited by 28
Diversity of T Cell Epitopes in Plasmodium falciparum Circumsporozoite Protein Likely Due to Protein-Protein Interactions
Aragam, N., Thayer, K. M., Nge, N. M., Hoffman, I., Martinson, F. E. A., Kamwendo, D., Lin, F., Sutherland, C. J., Bailey, J. A., & Juliano, J. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062427 · Cited by 24
Comparative population structure of Plasmodium falciparum circumsporozoite protein NANP repeat lengths in Lilongwe, Malawi
Bowman, N. M., Congdon, S., Mvalo, T., Patel, J. C., Escamilla, V., Emch, M., Martinson, F. E. A., Hoffman, I., Meshnick, S. R., & Juliano, J. J. (2013) · Scientific Reports · doi:10.1038/srep01990 · Cited by 28
Whole Pichia pastoris Yeast Expressing Measles Virus Nucleoprotein as a Production and Delivery System to Multimerize Plasmodium Antigens
Jacob, D., Ruffié, C., Dubois, M., Combredet, C., Amino, R., Formaglio, P., Gorgette, O., Pehau‐Arnaudet, G., Guery, C., Mercereau‐Puijalon, O., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086658 · Cited by 27

Authors: The RTS, S. C. T. P.
Affiliations: Program for Appropriate Technology in Health (US)
Corresponding author: The RTS,S Clinical Trials Partnership
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2012-12-13
Volume: 367
Issue: 24
Pages: 2284-2295
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1208394
PMC: PMC10915853
OpenAlex: W2244674613
Cited by: 752
References: 31
Citations by year: 2026: 18 · 2025: 29 · 2024: 35 · 2023: 38 · 2022: 36 · 2021: 42 · 2020: 45 · 2019: 47 · 2018: 40 · 2017: 58 · 2016: 67 · 2015: 74 · 2014: 111 · 2013: 103 · 2012: 7
FWCI: 91.09
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: other-oa
Locations: New England Journal of Medicine (publishedVersion, other-oa)
PubMed (publishedVersion)
Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
IHI Repository (acceptedVersion)
PubMed Central (acceptedVersion)
LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
Funders: Bill and Melinda Gates Foundation
GlaxoSmithKline
Wellcome Trust (092654)
National Institutes of Health (CC999999)
Topics: Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Travel-related health issues
Keywords: RTS,S/AS01, malaria vaccine, infants, vaccine efficacy, clinical malaria, severe malaria, circumsporozoite protein, co-administration, immunogenicity, vaccine safety, Plasmodium falciparum, African infants, malaria prevention, vaccine adverse events
MeSH terms: Africa, Female, Humans, Immunization Schedule, Infant, Male, Plasmodium falciparum, Vaccines, Synthetic, Incidence, Proportional Hazards Models, Malaria, Falciparum, Treatment Outcome, Malaria Vaccines, Intention to Treat Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks